Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Apnimed Q3 2026 Results: Net Loss of $29.5M, Loss Widens

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on its lead product candidate, Oxnimbi, which has completed Phase 3 clinical trials. The company reports significant operating losses since inception and anticipates requiring substantial additional funding to support its commercialization efforts and regulatory approval processes.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.58.8
Profit before tax-29.5-8.7
Net income-29.5-10.9
EPS (diluted, $ a share)$-1.05$-2.29

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-71.8%
Source

10-Q filed with the SEC, NASDAQ: APMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Apnimed, Inc.: key numbers

Share price
$16.28Close, Nov 16
Market cap
$678M
Shares outstanding
41.63MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Apnimed, Inc.

All →
8:05 AM ET 8-K
Financial Results

Apnimed Financial Results

Apnimed reported third quarter 2026 financial results, highlighting a cash position of $351.8 million following its upsized IPO in August. The company's NDA for AD109 (Oxnimbi) for the treatment of obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027.

“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story.”

Kevin Lind, Chief Executive Officer of Apnimed
4:46 PM ET 8-K
Other 8-K Filing

Apnimed Other 8-K Filing

Apnimed, Inc. announced that its previously issued financial statements for the three and six months ended June 30, 2026, should no longer be relied upon due to an accounting error. The error involves the misclassification of an $85.4 million gain from the sale of its interest in Shionogi-Apnimed Sleep Science, LLC as continuing operations rather than discontinued operations. The company intends to file a restatement on Form 10-Q/A to correct the classification, which does not impact total net income, cash, or total assets.

Counterparty
Shionogi & Co., Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.